← boardnext 2026-09
PCSA
Processa Pharmaceuticalsdistress 7/10 · high distress / dilution risk$2.54+13%today-79% from 52w high
Lead: metastatic breast cancer · est. market ~$35B (approx, global)
Revenue
pre-revenue
Liquidity
$2M
Runway
0.1 yrs
Shares 1y
-94%
Price & events
-19.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
+13.4%
1D
+6.3%
1W
+22.1%
1M
-17.3%
3M
-19.9%
6M
-59.4%
1Y
-93.8%
2Y
-99.9%
5Y
-99.9%
All
Overview
- Market Cap
- $6.99M
- Volume
- 112.10K
- 52 Week Range
- $1.85 – $11.97
- Total Shares
- 2.75M
- Float Shares
- 2.64M
- Short %
- 3.63%
- % Held by Insiders
- 14.90%
- % Held by Institutions
- 10.24%
- RVOL
- 1.61x
- Beta
- 0.99
Pipeline stages · 1 programs
PCS6422 and capecitabine, Capecitabine
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-09 Estimated 50% readout ~2026-10-16 | Phase 2 | PCS6422 and capecitabine, Capecitabine | Breast Cancer, TNBC - Triple-Negative Breast Cancer, HER2-negative Breast Cancer | — | recruiting |
Catalyst news & presentations · 9
- second half of 2025readoutPhase 2PCS6422 · Initial interim data from Phase 2 trialSEC 8-K
- 2025-08-04partnershipPrivate placement with accredited investor raising ~$1.3M gross proceeds.SEC 8-K
- 2025-07-01partnershipPCS12852 · Signed binding term sheet granting Intact Therapeutics exclusive option to licenseSEC 8-K
- mid-2025readoutPhase 2NGC-Cap · Initial data readout expected mid-2025SEC 8-K
- 2025-06-27withdrawalPCS3117 · Terminated licensing agreement, returning rights to original licensorSEC 8-K
- 2025-06-17partnershipPCS12852 · Binding term sheet with Intact Therapeutics for exclusive option to license Phase 2B-ready 5HT4 agonist for gastroparesis.SEC 8-K
- October 2, 2024trial initiationsecondaryPhase 2NGC-Cap · First patient dosed in Phase 2 clinical trial of NGC-CapSEC 8-K
- third quarter of 2024trial initiationsecondaryPhase 2NGC-Cap · First patient enrollment expected in Q3 2024SEC 8-K
- 2024-07-30fda agreementNGC-Cap · FDA cleared IND application for Phase 2 trial in breast cancerSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2025-09-02HC Wainwright & Co.Buy
- 2025-06-30HC Wainwright & Co.Buy
- 2024-12-05HC Wainwright & Co.Buy
- 2024-08-20HC Wainwright & Co.Buy
- 2024-08-19HC Wainwright & Co.Buy
- 2024-08-01HC Wainwright & Co.Buy
Competitors — metastatic breast cancer
Recent news
- 2026-07-21Realignment Talks Heat Up Thanks to PCSA - The Clemson Insider
- 2026-07-15Greg: ACC Commish Jim Phillips 'Hopeful' for PCSA Legislation Passage - On3
- 2026-07-14LSU Opposes PCSA | MLB Draft + LSU Is Draft Winners | SEC Media Narratives vs Reality - Westwood One Sports
- 2026-07-10PCSA Q4 2025 Earnings: Deeper Loss Per Share Yet Stock Rises 4.2% – Investor Focus Shifts to Pipeline Progress - Tax Rate Impact - dars.gov.et
- 2026-07-10Processa Pharmaceuticals (PCSA) Q4 2025 Earnings: Wider-than-Expected Loss Highlights Pre-Revenue Challenges - dars.gov.et
- 2026-07-09PCSA Q4 2025 Earnings: Deeper Loss Per Share Yet Stock Rises 4.2% – Investor Focus Shifts to Pipeline Progress - Margin Expansion Trends - dars.gov.et
- 2026-07-09DOLE Davao Honors Public Service Through Active Participation in 125th PCSA Activities - Department of Labor and Employment
- 2026-07-08Big 12 commissioner Brett Yormark on Texas Tech, CFP expansion, PCSA - The Des Moines Register
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.